Casey House creates fictitious drug, Stigmavir, to smash HIV stigma within the health care system
29 mai 2024 06h30 HE
|
Casey House
TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Casey House – a hospital unlike any other providing care to those living with and at risk of HIV – today announces the launch of its latest advocacy campaign,...
Animal Healthcare Market is Set to Soar to USD 60.3 Billion by 2033, Unleashing Tremendous Growth Potential: Persistence Market Research
12 juil. 2023 14h53 HE
|
Persistence Market Research
New York, July 12, 2023 (GLOBE NEWSWIRE) -- The global animal healthcare market size was valued at USD 39.01 billion in 2022 and is projected to reach USD 60.3 billion by 2033, growing at a CAGR of...
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agent
24 août 2022 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Michio Kurosu, PhD, Professor, Department...
Anti-Infective Agents Market Size Worth $164.1Bn Globally, by 2028 at 3.19% CAGR - Exclusive Report by The Insight Partners
13 juil. 2022 09h04 HE
|
The Insight Partners
New York, July 13, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Anti-Infective Agents Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type,...
AB Science annonce aujourd'hui avoir reçu l'autorisation de reprise des inclusions de patients dans l'étude de phase 2 du masitinib dans la COVID-19 (AB20001)
16 sept. 2021 13h34 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REÇU L'AUTORISATION DE REPRISE DES INCLUSIONS DE PATIENTS DANS SON ÉTUDE DE PHASE 2 DU MASITINIB DANS LA COVID-19, CE QUI SIGNIFIE LA REPRISE DU...
AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
16 sept. 2021 13h34 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED AUTHORIZATION TO RESUME PATIENT ENROLLMENT IN ITS PHASE 2 COVID-19 STUDY OF MASITINIB, SIGNIFIYING RESUMPTION OF RECRUITMENT IN ALL THREE OF...
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
10 août 2021 07h00 HE
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma CEO Issues Letter to Shareholders
15 avr. 2021 07h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
12 janv. 2021 08h30 HE
|
AzurRx BioPharma, Inc.
Patent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI infectionsCOVID-19 GI infections are a significant unmet clinical need; AzurRx estimates potential U.S....
Anti-Microbial Coatings Market to Reach $11.6 Billion by 2027 | CAGR: 13.3%: AMR
22 oct. 2020 09h00 HE
|
Allied Market Research
Portland, OR, Oct. 22, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global anti-microbial coatings market generated $4.0 billion in 2019, and is...